oxybutynin has been researched along with Dermatoses in 8 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 7.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 3.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "Since the effect of a percutaneous absorption-type dopamine agonist (DA) preparation, rotigotine patch, stably persists by once-a-day application, this dosage form is appropriate for Parkinson's disease patients showing levodopa induced wearing off phenomenon." | 1.46 | [Efficacy of Topical Agents for Symptomatic Treatment of Rotigotine Patch-Induced Skin Disorders]. ( Fujioka, S; Hara, K; Kamimura, H; Kiyomi, F; Ogata, K; Shibaguchi, H; Tsuboi, Y; Yasutaka, Y, 2017) |
| "The higher frequency of atropinic reactions in children may be due to the higher dosage of the drug used and/or to differences in hydroxylation metabolism, that is genetically determined in adults." | 1.29 | [Adverse effects of oxybutynin chloride (Ditropan) in pediatrics]. ( Autret, E; Barbellion, M; Dutertre, JP; Jonville, AP, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Laustsen, G | 1 |
| Wimett, L | 1 |
| Jonville, AP | 1 |
| Dutertre, JP | 1 |
| Barbellion, M | 1 |
| Autret, E | 1 |
| Chiba, T | 1 |
| Takahashi, H | 1 |
| Tairabune, T | 1 |
| Kimura, S | 1 |
| Ueda, H | 1 |
| Kudo, K | 1 |
| Yasutaka, Y | 1 |
| Fujioka, S | 1 |
| Shibaguchi, H | 1 |
| Kiyomi, F | 1 |
| Hara, K | 1 |
| Ogata, K | 1 |
| Tsuboi, Y | 1 |
| Kamimura, H | 1 |
| Ghalayani Esfahani, A | 1 |
| Altomare, L | 1 |
| Varoni, EM | 1 |
| Bertoldi, S | 1 |
| Farè, S | 1 |
| De Nardo, L | 1 |
| Antaya, RJ | 1 |
| del Carmen, M | 1 |
| Alonso, F | 1 |
| Sukumar, N | 1 |
| Yong, F | 1 |
| Dvoretzky, I | 1 |
| Tamayol, A | 1 |
| Akbari, M | 1 |
| Zilberman, Y | 1 |
| Comotto, M | 1 |
| Lesha, E | 1 |
| Serex, L | 1 |
| Bagherifard, S | 1 |
| Chen, Y | 1 |
| Fu, G | 1 |
| Ameri, SK | 1 |
| Ruan, W | 1 |
| Miller, EL | 1 |
| Dokmeci, MR | 1 |
| Sonkusale, S | 1 |
| Khademhosseini, A | 1 |
| BASTENIER, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca[NCT01746056] | 73 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxybutynin and Dermatoses
| Article | Year |
|---|---|
Drug approval highlights for 2003.
Topics: Acyclovir; Cardiovascular Agents; Cardiovascular Diseases; Dermatologic Agents; Drug Approval; Estro | 2004 |
1 trial available for oxybutynin and Dermatoses
| Article | Year |
|---|---|
An Open Label Study of an Occlusive Heat Patch in the Treatment of Warts
Topics: Administration, Cutaneous; Child; Female; Fingers; Hand; Hot Temperature; Humans; Hyperthermia, Indu | 2019 |
6 other studies available for oxybutynin and Dermatoses
| Article | Year |
|---|---|
[Adverse effects of oxybutynin chloride (Ditropan) in pediatrics].
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Hypersensitivity; Drug Infor | 1993 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
[Efficacy of Topical Agents for Symptomatic Treatment of Rotigotine Patch-Induced Skin Disorders].
Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Male; Middle Aged; Retrospective | 2017 |
Electrophoretic bottom up design of chitosan patches for topical drug delivery.
Topics: Administration, Topical; Chitosan; Clobetasol; Delayed-Action Preparations; Drug Carriers; Drug Comp | 2019 |
Flexible pH-Sensing Hydrogel Fibers for Epidermal Applications.
Topics: Alginates; Animals; Calcium Chloride; Cell Line; Glucuronic Acid; Hexuronic Acids; Hydrogels; Hydrog | 2016 |
[Patch test techniques used for the diagnosis of occupational dermatoses].
Topics: Occupational Health; Patch Tests; Skin Diseases; Transdermal Patch | 1951 |